The two herbs the men's health supplement market has paired together since 2020. One has a real evidence base. The other has a smaller one. Neither replaces TRT.
Evidence and pricing are current as of May 2026; new trials may change the picture.
Executive Summary
Tongkat Ali (Eurycoma longifolia) and Fadogia agrestis are the two herbs that have dominated the men's testosterone-supplement conversation since approximately 2020. The pairing was popularized in optimization-medicine influencer content and has become so standardized that many commercial products bundle them in a single capsule. The clinical evidence for the two is not equivalent — Tongkat Ali has a substantial and growing human trial literature; Fadogia agrestis has essentially zero published human trials and rests on a small animal study base.
This is a companion to the existing Vanguard monographs on Tongkat Ali and Fadogia Agrestis individually. This piece is the direct comparison plus the honest assessment of whether the standard pairing is justified by the evidence — and whether either replaces or supplements testosterone replacement therapy in patients with documented hypogonadism.
The honest 2026 framing: Tongkat Ali at 200–400 mg/day of standardized extract has measurable but modest effects on testosterone, libido, and stress markers in human trials, with a reasonable safety profile and a defined mechanism (cortisol modulation and reduced SHBG). Fadogia agrestis has been demonstrated to raise testosterone in male rats but has essentially no human clinical evidence; the pairing with Tongkat Ali in commercial products has been driven by influencer marketing rather than clinical data. Neither herb produces testosterone changes comparable to even modest testosterone replacement therapy, and neither is appropriate as a substitute for clinically indicated TRT.
What the evidence supports today:
- Tongkat Ali has multiple controlled human trials supporting modest effects on testosterone, libido, mood, and stress markers.
- Fadogia agrestis has essentially no human clinical evidence — the case is built on a small rat literature.
- Neither herb produces testosterone changes comparable to TRT; both should be framed as adjunctive interventions, not substitutes for clinical hypogonadism treatment.
Mechanism Differences
Tongkat Ali
Tongkat Ali is the root extract of Eurycoma longifolia, a Southeast Asian plant traditionally used for fatigue, stress, and male sexual function. The active constituents are a family of quassinoids including eurycomanone, which is the most-studied bioactive. Proposed mechanisms include modest aromatase inhibition (reducing testosterone-to-estradiol conversion), modulation of cortisol metabolism (reducing stress-related cortisol elevation, which indirectly supports testosterone levels), and possibly direct effects on sex hormone binding globulin (SHBG) reducing the binding of testosterone and increasing free testosterone availability.
The mechanism profile is plausible and defined. The effect sizes in human trials are real but modest — typically mild increases in total testosterone, without evidence for a universal 10–20% estimate or consistent increases in free testosterone, alongside reductions in cortisol and improvements in stress-related subjective measures.
Fadogia Agrestis
Fadogia agrestis is a West African shrub traditionally used as an aphrodisiac and for various other indications. The active constituents are less well-characterized; the proposed primary mechanism is direct stimulation of testicular Leydig cells to increase testosterone synthesis. The mechanistic case rests on a small set of rat studies, primarily one 2005 publication that showed substantial testosterone increases in male rats after Fadogia extract administration.
The rat data are real. The translation to humans has not been performed. There are no published controlled human trials of Fadogia agrestis showing testosterone effects, safety effects, or any other outcome. The supplement industry has built a substantial product category on essentially zero human evidence.
Clinical Evidence Comparison
| Evidence category | Tongkat Ali | Fadogia agrestis |
| Human RCTs | Multiple (n=10+ trials) | Essentially none |
| Animal evidence | Extensive | Limited (~1 main rat study) |
| Testosterone effect (humans) | Modest measurable increase | Unstudied in humans |
| Safety data (humans) | Reasonable, multiple trial cohorts | Essentially absent for humans |
| Mechanism characterization | Reasonably defined | Less defined |
The Pairing Question
The standard commercial pairing of Tongkat Ali and Fadogia is supported by influencer marketing but not by clinical data. There is no published trial of the combination in humans. The mechanistic rationale offered for the combination — that Tongkat Ali reduces cortisol and SHBG (preserving testosterone) while Fadogia stimulates testicular testosterone production (raising testosterone) — is biologically plausible but uncharacterized in human trials.
For the patient considering the pairing, the practical question is whether Fadogia adds anything to Tongkat Ali alone. The available human evidence does not support a clear answer: Tongkat Ali alone has documented effects; Fadogia in addition has not been studied in humans. The combination may or may not produce meaningful incremental benefit over Tongkat Ali alone.
Comparison to Testosterone Replacement Therapy
Neither herb produces testosterone changes comparable to TRT. Standard TRT (testosterone cypionate 100–200 mg weekly, or transdermal testosterone) produces total testosterone increases of 200–500 ng/dL or more in hypogonadal men. Tongkat Ali's measured effects are typically 10–20% increases on baseline — meaningful at the margins but not in the same range as TRT. Fadogia's effect in humans is unknown.
For a patient with documented hypogonadism (consistently low LC-MS/MS testosterone, hypogonadal symptoms, hypogonadotropic pattern on workup), neither herb is appropriate as a substitute for clinical TRT. Both are reasonable as adjuncts for users not pursuing TRT or for users in the borderline-low range exploring herbal options before considering TRT.
Quality and Standardization
Tongkat Ali extract quality varies substantially. The most-studied and most clinically supported form is standardized to a specific eurycomanone content — typically 1–2% eurycomanone in the extract. Look for products specifying standardization rather than generic "Tongkat Ali extract." Major branded ingredients (LJ100, Physta) have specific standardization profiles and trial support.
Fadogia agrestis extract quality is essentially uncharacterized. Standardization is rare. Identity and purity testing across commercial brands is limited. The supplement-channel supply chain quality is variable in ways that the buyer typically cannot assess.
Cost Comparison
Standardized Tongkat Ali extract: typically $20-50/month for a quality branded product at 200-400 mg/day. Fadogia agrestis extract: typically $25-50/month. Combined products: $30-60/month. The cost is not the dominant decision factor; the evidence base differential is.
How a Clinician Might Frame Tongkat Ali vs Fadogia
- Strongest case for Tongkat Ali alone: Adult man with mild testosterone-related symptoms (mood, libido, energy) without clinical hypogonadism, interested in evidence-supported herbal intervention, willing to commit to 4-12 week trial with realistic expectations about modest effect magnitude.
- Reasonable case for the combination: Same patient population, accepting that Fadogia adds essentially unstudied mechanism on top of Tongkat Ali's modest documented effects. Cost-benefit is uncertain.
- Weakest case: Either herb as substitute for clinically indicated TRT in documented hypogonadism. The effect sizes do not match TRT and the consequences of inadequate testosterone replacement in true hypogonadism are real (loss of bone density, depression, sexual dysfunction).
Tongkat Ali is a legitimate herbal intervention with measurable modest effects and a reasonable safety profile. Fadogia agrestis is a supplement product built largely on rat data and influencer marketing without supporting human evidence. The standard commercial pairing is supported by neither clinical trial data nor strong mechanistic theory. For the patient considering this category: Tongkat Ali alone is reasonable; the addition of Fadogia adds speculation more than proven benefit. Neither replaces appropriate clinical care for documented hypogonadism.
Educational Disclaimer
This monograph is published by Vanguard Optimization as physician-led, evidence-based education. It is not medical advice. We do not prescribe, diagnose, or establish doctor–patient relationships. Decisions about supplementation or medication should be made with the clinician who knows you and your specific clinical situation. The signal-grading and editorial choices in this document represent our best read of the published literature as of May 2026; new data may change them.
Key References
Talbott SM, et al. Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr. 2013.
George A, Henkel R. Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy. Andrologia. 2014.
Yakubu MT, et al. Aphrodisiac potentials of the aqueous extract of Fadogia agrestis stem in male albino rats. Asian J Androl. 2005.
Henkel RR, et al. Tongkat Ali (Eurycoma longifolia) prevents osteoporosis in androgen-deficient state — extensive review of human evidence.
Various commercial Tongkat Ali extract documentation (LJ100, Physta) and Fadogia supplement-industry materials, 2020-2026.